[Skip to Content]
[Skip to Content Landing]
Views 1,185
Citations 0
Comment & Response
February 19, 2014

Short-Acting β-Blocker Administration in Patients With Septic Shock

Author Affiliations
  • 1Department of Preventive Medicine, Northwestern University, Chicago, Illinois
JAMA. 2014;311(7):737. doi:10.1001/jama.2014.312

To the Editor Dr Morelli and colleagues1 reported that for patients with septic shock, open-label intravenous use of esmolol was associated with reductions in heart rates to target levels without increased adverse events compared with standard care. In sepsis, outcomes are associated with the burden of infecting pathogens, adherence to the guidelines of the SSC,2 and host immunity.

First Page Preview View Large
First page PDF preview
First page PDF preview